Genelabs' Prestara Phase III Does Not Confirm Bone Mineral Density Effect
This article was originally published in The Pink Sheet Daily
Executive Summary
The trial was designed to meet FDA's "approvable" letter request for confirmation of bone mineral density increases in women with lupus receiving glucocorticoids. Genelabs plans to meet with the agency when it completes data analysis.